PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rituximab - Connective tissue disease
PAD Profile : Rituximab - Connective tissue disease Important
Keywords :
interstitial lung disease
Brand Names Include :
Truxima, Mabthera, Rixathon
Important Information :
Specialist centres only
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Immune thrombocytopenia
- Refractory vasculitis
- Rheumatoid arthritis
- Systemic Lupus Erythematosus
- Sjogren's syndrome
- Chronic inflammatory demyelinating polyneuropathy
- Any paediatric use
- ANCA-positive vasculitis
- Graft versus Host Disease (GVHD)
- Myositis
- Immunoglobulin G4 related disease
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
16 April 2018
Not Set
This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Associated BNF Codes
08. Malignant Disease and Immunosuppression
08.02.03. Anti-lymphocyte monoclonal antibodies
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs